Search
Systemic Lupus Erythematosus Clinical Trials
A listing of 48 Systemic Lupus Erythematosus clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 48
There are currently 48 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
Recruiting
This is a Phase 1 study to evaluate the safety and efficacy of a single infusion of CB-010 in patients with refractory Systemic Lupus Erythematosus (SLE) with cohorts for lupus nephritis (LN) and extrarenal lupus (ERL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Oncology Hematology Care, Cincinnati, Ohio
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Recruiting
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/17/2025
Locations: Research Site, Las Vegas, Nevada
Conditions: Systemic Lupus Erythematosus
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Recruiting
Background:
People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus.
Objective:
To test whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with SLE.
Eligibility:
People aged 18 to 80 years with SLE.
Design:
Participants will undergo screening. Th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/17/2025
Locations: Sl0044 50058, Avondale, Arizona +127 locations
Conditions: Systemic Lupus Erythematosus
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include:
* Study duration: 36 weeks
* Treatment duration: 24 weeks
* Visit frequency: every 2 weeks
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Accel Research Sites Network - Birmingham- Site Number : 8400003, Birmingham, Alabama +70 locations
Conditions: Systemic Lupus Erythematosus
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
04/15/2025
Locations: AZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona +324 locations
Conditions: Systemic Lupus Erythematosus
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +53 locations
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2025
Locations: Medvin Clinical Research - Metyas ( Site 0128), Covina, California +118 locations
Conditions: Systemic Lupus Erythematosus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/11/2025
Locations: UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California +198 locations
Conditions: Systemic Lupus Erythematosus
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
Recruiting
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/10/2025
Locations: University of Colorado, Aurora, Colorado +4 locations
Conditions: Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Study of Systemic Lupus Erythematosus
Recruiting
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.
Patients 3 years of age and older with known or suspected SLE and their relatives may be eligible for this study. Patients will be evaluated with a medical history and physical examination, blood and urine tests. Other procedures may include:
1. Electrocardio... Read More
Gender:
ALL
Ages:
Between 3 years and 120 years
Trial Updated:
04/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Systemic Lupus Erythematosus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2025
Locations: University of California Irvine, Orange, California +21 locations
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
1 - 12 of 48